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Available online 2 May 2018Studies assessing prematuremortality in peoplewith severemental illness (SMI) are usually based in one setting,
hospital (secondary care inpatients and/or outpatients) or community (primary care). Thismay lead to ascertain-
ment bias. This study aimed to estimate standardised mortality ratios (SMRs) for all-cause and cause-specific
mortality in people with SMI drawn from linked primary and secondary care populations compared to the gen-
eral population. SMRswere calculated using the indirect method for a United Kingdom population of almost four
million between 2004 and 2013. The all-cause SMRwas higher in the cohort identified from secondary care hos-
pital admissions (SMR: 2.9; 95% CI: 2.8–3.0) than from primary care (SMR: 2.2; 95% CI: 2.1–2.3) when compared
to the general population. The SMR for the combined cohort was 2.6 (95% CI: 2.5–2.6). Cause specific SMRs in the
combined cohort were particularly elevated in those with SMI relative to the general population for ill-defined
and unknown causes, suicide, substance abuse, Parkinson's disease, accidents, dementia, infections and respira-
tory disorders (particularly pneumonia), and Alzheimer's disease. Solely hospital admission based studies, which
have dominated the literature hitherto, somewhat over-estimate premature mortality in those with SMI. People
with SMI are more likely to die by ill-defined and unknown causes, suicide and other less common and often
under-reported causes. Comprehensive characterisation of mortality is important to inform policy and practice
and to discriminate settings to allow for proportionate interventions to address this health injustice.eral Pra
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The increased risk of premature death in people with severe mental
illness (SMI) compared to the general population is well established
(Brown et al., 2000; Hayes et al., 2017; Osborn et al., 2006). Studies to
date havemostly been based in one setting, hospital (secondary care in-
patient and/or outpatients) or community (primary care), rather than
using linked population level data, and have consistently reported a
two to three fold increase in all-causemortality ratios. This corresponds
to a reduction in life expectancy of 10–20 years for those with SMI – a
clear health injustice. It is often assumed that studies based in the sec-
ondary healthcare setting are unlikely to bias findings on this mortality
gap since most people with SMIs are likely to have accessed secondaryctice Database; ICD,
tistics; PEDW, Patient
Linkage; SMI, severe
mographic Service.
hool, ILS2, Swansea
n open access article undercare (Jayatilleke et al., 2017). However, this assumption isworth explor-
ing. Mortality risk may be over or under estimated since more serious
and vulnerable cases will be over-represented in hospital inpatient
and outpatient settings (Amaddeo et al., 1995; Carney et al., 2006;
Copeland et al., 2009; Crump et al., 2013; Jayatilleke et al., 2017;
Kessler et al., 2005) and possibly under-represented in community/pri-
mary care settings (Hayes et al., 2017; McDermott et al., 2005; Osborn
et al., 2007; Osborn et al., 2006). Here, we report what is to our knowl-
edge thefirst analysis ofmortality risk using person level linked hospital
and primary care data to explore the extent towhich ascertainment bias
has played a part in risk estimates from previous studies based in one
setting alone (hospital or primary care).
Some causes associated with this premature mortality are well doc-
umented. Suicide risk in those with SMI is highly associated with acute
psychotic episodes and psychiatric hospitalisation, peaking during ad-
mission and shortly after discharge (Appleby et al., 2001; Nordentoft
et al., 2013). People with SMI often have poor physical health and
greater levels of obesity than the general population (Leucht et al.,
2007). Deaths from cardiovascular, metabolic and respiratory diseases
are common and account for most of the excess mortality from naturalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Copeland et al., 2009; Correll et al., 2017; Jayatilleke et al., 2017;
Olfson et al., 2015; Osborn et al., 2007). A number of physical comorbid-
ities were particularly over-represented in a recent study using a large
primary care database (Olfson et al., 2015). These included Parkinson's
disease and some disorders of the liver and the digestive system, with
diseases such as epilepsy, diabetes, and respiratory disorders notably el-
evated in comparison to the general population. Many studies only re-
port on common causes of natural deaths, while less common causes
are under-reported, often due to insufficient sample sizes. Hence, in
the present study we aimed to report a comprehensive assessment of
mortality in people with SMI drawn from primary and secondary care
populations compared to the general population.
2. Materials and methods
2.1. Design
A retrospective electronic cohort study.
2.2. Study population and setting
The whole population of 3.9 million individuals in Wales,
2004–2013, was included in the study. SMI diagnoses were divided
into three groups based on the diagnostic categories in the International
Classification of Diseases (ICD) version 10 and Read Codes version 2:
1) schizophrenia, schizotypal and delusional disorders; 2) bipolar disor-
der and other mood related disorders; 3) other severe mental illness
(Read Codes only relating to ‘other non-organic psychoses’). Supple-
mentary Table 1 lists study related ICD-10 codes.
2.3. Data source
The Farr Institute's Secure Anonymised Information Linkage (SAIL)
databank (www.saildatabank.com) was used in the study. SAIL is an
expanding data repository (around 3 billion records) of anonymised
person based linkable data from healthcare and public settings to sup-
port research. Policies, processes, structures and controls to manage
and maintain this databank have been described elsewhere (Ford
et al., 2009; Lyons et al., 2009). We utilised the following datasets in
our study:
1. The Office for National Statistics (ONS) deaths register, which houses
nationwide information on cause covering the whole population of
Wales.
2. General Practice Database (GPD), which contains diagnoses, symp-
toms, investigations, prescribedmedication, referrals, coded hospital
contacts and test results. At time of analysis 71% (338/474) of all gen-
eral practices in Wales were supplying SAIL with their data.
3. Patient Episode Database for Wales (PEDW), an NHSWales hospital
admissions dataset comprising clinical information of all hospital ad-
missions (inpatient and day cases) covering the whole population of
Wales.
4. Welsh Demographic Service (WDS) an administrative register of all
individuals in Wales that use NHS services, which includes
anonymised demographics and practice registration history.
2.4. Measures
We used ICD-10 codes for SMI (Supplementary Table 1) to interro-
gate PEDW for both planned and emergency admissions identifying
SMI cases as the principal discharge diagnosis for hospitalisation as
done in previous studies assessing premature mortality (Ford et al.,
2009). We used Read Code version 2 to identify cases of SMI in the
GPD. Diagnostic codes used to identify people with SMI in the GPD
have been previously validated (Economou et al., 2012; Lloyd et al.,
2015). Diagnoses related to SMI, number of deaths and cause of deathswere extractedwithin the study period (01/01/2004–31/12/2013). ICD-
10 codes were used to classify cause of death and were grouped into
main categories. We further categorised causes of death into natural
and unnatural (accidents, assault, suicide, self-harm and undetermined
intent). Supplementary Table 2 tabulates categories and sub-categories
of causes of death aswell as the corresponding ICD-10 codes used in the
study.
2.5. Analysis
We utilised the WDS to collect demographic information, such as
week of birth and sex. The age of each individual was calculated at the
midpoint of the follow-up period and described according to the follow-
ing categories: under 45, 45–64, 65–84 and 85 or above years in accor-
dance with other studies of this type (Hoang et al., 2011).
Standardisedmortality ratios (SMRs)were calculated using the indi-
rect method with the WDS population as the standard population. We
estimated SMRs for four sets of patient cohorts identified as follows:
a) Primary care cohort: patients with a SMI diagnosis from the GPD
within the study period using a previously validated algorithm
(Economou et al., 2012; Lloyd et al., 2015);
b) Primary care cohort with no hospital admissions: patients with at
least one GP diagnosis related to SMI but without subsequent inpa-
tient diagnosis for the same disorder within the study period;
c) Secondary care cohort: patients with a principal diagnosis from
PEDW (inpatient diagnosis) related to SMI within the study period;
and
d) Combined cohort: combining the primary (a) and secondary
(c) cohorts.
The start date of the follow-up period was defined as the date of the
first inpatient or GP SMI related diagnoses within the study period (01/
01/2004–31/12/2013). An individual was included in the cohort once
only. The end date was the death date, the end of the study period
(31/12/2013) or the last end date of registration in the WDS within
the study period, whichever came first. For the combined primary and
secondary cohort (combined cohort), the start date of the follow-up pe-
riod was the earlier date of either the GP or inpatient diagnosis. For in-
dividuals with no SMI related diagnosis, the start date of the follow-up
period was the beginning of the study period (01/01/2004) and the
end date was the death date or the end of the study period, whichever
came first.
All-cause and cause-specific mortality rates were calculated using
the person years at risk corresponding to the follow-up periods (IARC
Working Group on the Evaluation of Carcinogenic Risks to Humans,
2010; Ressing et al., 2010). SMRs were calculated by dividing the ob-
served numbers of deaths in the SMI cohorts (primary care, primary
care without hospital admission, secondary care and combined cohort)
by the expected number of deaths derived from the age (5-year age
bands) and sex-matched all-cause and cause-specific mortality rates
found in the whole of Wales. SMRs for causes with a small number of
observed deaths (e.g., diseases of the eye and ear) were not reported
(refer to Supplementary Table 2).
We further characterised the four cohorts by age, sex, diagnostic cat-
egory and stratified by underlying causes of death. To calculate SMRs for
the cause of death of people within SMI categories, we used the rates
from the corresponding specific causes within the population of
Wales. We conducted further additional analyses to make comparisons
between SMRs for specific causes of death between cohorts sourced
from primary care and secondary care settings.
Data in the SAIL databank were interrogated using structured query
language (SQL DB2). All confidence intervals (CIs) of the SMRs were
two-tailed mid-p exact CIs, assuming Poisson distribution for the ob-
served deaths, and were calculated as previously described (Rothman
156 A. John et al. / Schizophrenia Research 199 (2018) 154–162and Boice Jr, 1979). CIs for proportions and percentages were estimated
by the Wilson score method with continuity correction (Newcombe,
1998).
2.6. Ethical approval
The use of data in the SAIL databank for this study have the required
permissions from the SAILindependent Information Governance Re-
view Panel, which includes representatives with a variety of expertise
from different organisations: BMA, NRES, Involving People, NHS Wales
Informatics Service and Public Health Wales NHS Trust. This study
forms part of the “PsyCymru study” (Lloyd et al., 2015) ethically ap-
proved by Wales REC 3 (14/WA/1136).
3. Results
3.1. Participants, number of deaths and demographics
The standard populationwas thewhole population ofWales inWDS
over the ten-year observation period. This consisted of 3.9 million peo-
ple providing 35.3million years of person timewith 377,511 deaths ob-
served. In the primary care cohort sourced from GPD, there were 2720
deaths over 112,316 person years, provided by 21,589 individuals
with a SMI diagnosis. Of these, 37.8% (8163/21,589) also had hospital
admissions and were present in the secondary care cohort. For the re-
maining patients within the primary care cohort (i.e., those seen in pri-
mary care and/or with recorded out-patient appointments where no
hospitalisation for the same SMI occurred) we observed 1753 deaths
out of 62,459 person years provided by 13,426 individuals. In the sec-
ondary care cohort, there were 2956 deaths within the 83,300 person
years contributed by 16,371 individuals diagnosedwith a SMIwith hos-
pital admissions.
In the combined cohort, there were 4709 deaths out of 153,263 per-
son years, contributed by 29,797 individuals who had received a diag-
nosis of SMI recorded in either primary care or secondary care. For
this combined cohort, 27.5% (8208/29,797) were sourced from second-
ary care cohort (hospital admissions only), 45.1% (13,426/29,797) were
from the primary care cohort (GP and recorded out-patients), and 27.4%
(8163/29,797) were from both primary and secondary cohorts, i.e., had
a SMI diagnosis recorded in primary care and also had a hospital
admission.Fig. 1. Forest plot showing all-cause SMR (white diamonds and the associated number labels) f
(light shaded region) represents observed deaths fewer than the expected deaths derived fro
observed deaths greater than the expected deaths. Error bars: 95% CIs.The distribution in terms of demographics (sex, age, deprivation)
across each cohort is shown in Supplementary Table 3. Sex was evenly
divided (50/50). Almost half of the cases were under 45 years (40.8%–
47.3%) and 26.2%–26.8% resided in the most deprived quintile at the
start of follow-up (ranges across all cohorts). Those in the hospital ad-
missions secondary care cohort included lower percentages of under
45 year olds and those from the least deprived quintile compared to
all the other cohorts. Over a third (N36%) had bipolar disorder, Schizo-
phrenia ranged from 46.9% to 62.1% across settings with other SMI ac-
counting for the remainder.
3.2. All-cause SMRs for different cohort ascertainment methods
Themortality ratios (andCIs) for cohorts ascertained from thediffer-
ent settings are illustrated in the forest plot (Fig. 1). We foundmortality
ratios to be higher for the secondary care hospital admissions cohort
(2.9; 95% CI: 2.8–3.0) than for the primary care cohort (2.2; 95% CI:
2.1–2.3), as well as the primary care cohort without hospital admission
(2.3; 95% CI: 2.2–2.4) when compared to the general population of
Wales. The all-cause SMR was 2.6 (95% CI: 2.5–2.6) for the combined
cohort.
3.3. All-cause SMRs in the combined cohort
The range of age at death in the combined cohort was 15–108 years
old;with themean age at death being 72.7 years old. The breakdown by
age groups of age at death was: 9.8% (461/4709) were under 45 years;
21.2% (996/4709) aged 45–64 years; 47.1% (2216/4709) aged
65–84 years; and 22.0% (1036/4709) of deaths aged 85 years and over.
The all-cause SMRs for all those with SMI and for SMI categories by
age and sex in the combined cohort are summarised in Table 1. Males
(SMR: 3.0; 95% CI: 2.9–3.2) had higher all-cause SMR than females
(SMR: 2.3; 95% CI: 2.3–2.4). Higher ratios were observed in the younger
age groups. Ratios for schizophrenia related disorders were higher
(SMR: 2.7; 95% CI: 2.6–2.8) than for people with bipolar and other
mood related psychotic disorders (SMR: 2.2; 95% CI: 2.1–2.3).
3.4. Cause-specific mortality in the combined cohort
Fig. 2 illustrates the proportion of deaths bymajor underlying causes
and the corresponding SMRs for the combined cohort. Nearly two-
thirds of all the deaths were from circulatory, respiratory disordersor people diagnosed with SMI by three cohort ascertainment methods. SMR less than one
m the general population while SMR greater than one (dark shaded region) represents
Table 1
All-cause SMRs for people diagnosed with SMI by sex and age group in combined cohort.
SMR
(95% CI)
Age (years)
Diagnostic groupa No. of deaths Overall Male Female b45 45–64 65–84 ≥85
All severe mental illness 4709 2.6 3.0 2.3 5.8 3.3 2.4 2.0
(2.5–2.6) (2.9–3.2) (2.3–2.4) (5.3–6.4) (3.1–3.5) (2.3–2.5) (1.9–2.1)
Schizophrenia, Schizotypal & delusional disorders 2681 2.7 3.3 2.3 6.8 3.8 2.5 1.8
(2.6–2.8) (3.1–3.5) (2.2–2.5) (6.1–7.5) (3.5–4.1) (2.3–2.6) (1.6–1.9)
Bipolar disorder & other mood related disorders 1565 2.2 2.4 2.1 4.1 2.8 2.0 1.6
(2.1–2.3) (2.2–2.6) (2.0–2.3) (3.4–4.9) (2.5–3.1) (1.9–2.1) (1.5–1.9)
Other non-organic psychotic disorders 654 3.2 3.8 2.9 5.1 2.3 3.7 2.8
(2.9–3.4) (3.3–4.2) (2.7–3.2) (3.5–7.8) (1.7–3.1) (3.3–4.2) (2.5–3.1)
a Refer to Supplementary Table 1 for the diagnoses included in each diagnostic group.
157A. John et al. / Schizophrenia Research 199 (2018) 154–162and cancers (61.8%). Diseases of the circulatory system alone accounted
for 28.4% (1339/4709) of all deaths; with ischaemic heart disease being
the most common. Deaths from respiratory diseases accounted for
17.8% of deaths (840/4709); with just under half attributable to pneu-
monia alone (418/840). Cancers accounted for 15.6% (735/4709) of all
deaths; the most common being lung and gastrointestinal cancer. 9.3%
(440/4709) of deaths were due to suicides (self-harm and events of un-
determined intent) and accidents. Deaths attributed to Alzheimer's, se-
nility and dementia taken together across ICD-10 categories accounted
for 11.8% (555/4709) of deaths.
Overall SMRs associated with specific cause of deaths examined in
the present study for the combined cohort are displayed in Table 2Fig. 2. Proportion of deaths by underlying causes (the outermost ring) and the corresponding S
cohort. * “Others” includes genitourinary, symptoms, signs and abnormal clinical findings (e
diseases plus a small number of other rarer causes. Note that SMR for “Others” are not shownand SMRs for males, female and age groups are summarised in
Table 3. SMRs associated with unnatural causes (SMR: 6.9; 95% CI:
6.2–7.5) were higher than with natural causes (SMR: 2.4; 95% CI:
2.3–2.5, see Table 2). In particular, males tended to have higher SMRs
than females for unnatural causes of death (males: SMR: 7.3; 95% CI:
6.4–8.1; females: SMR: 5.9; 95% CI: 5.0–6.8, Table 3). The highest
cause-specific SMR was for ill-defined or unknown causes (SMR: 13.3;
95% CI: 10.1–17.2) followed by suicide and events of undetermined in-
tent (SMR: 12.1; 95% CI: 10.6–13.8). The SMR for the latter was espe-
cially elevated in females (SMR: 21.4; 95% CI: 17.1–26.4). We further
compared suicide in the secondary care cohortwith the primary care co-
hort. The SMR for suicide for the secondary care cohortwas considerablyMR (polar bar chart with labelled values) in persons diagnosed with SMI in the combined
xcept ill-defined and unknown causes), infections, endocrine, nutritional and metabolic
for clarity. Reader may refer to Table 3 for the relevant values.
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158 A. John et al. / Schizophrenia Research 199 (2018) 154–162higher (SMR: 16.5; 95% CI: 14.1–19.1) than for the primary care cohort
(SMR: 8.9; 95% CI: 7.4–10.6) when compared to the general population.
For natural causes, we found the highest differences in mortality to
be deaths from Parkinson's(SMR: 5.4; 95% CI: 4.3–6.7). A cluster of cog-
nitive decline related deaths was also particularly elevated in compari-
son to the general population: dementia (SMR: 5.2; 95% CI 4.7–5.7);
Alzheimer's (SMR: 3.8; 95% CI: 3.0–4.6); and senility (SMR: 2.1; 95%
CI: 1.6–2.7). The ratio of deaths from respiratory diseases was found
to be high (SMR: 3.2; 95% CI: 3.0–3.4), particularly pneumonia (SMR:
3.8; 95% CI: 3.5–4.2). We also found the ratio of deaths from genitouri-
nary causes to be elevated (SMR: 2.8; 95% CI: 2.3–3.4). The ratios of
deaths attributable to diseases of the circulatory system (SMR: 2.2;
95% CI: 2.0–2.3), including cerebrovascular disease (SMR: 2.3; 95% CI
2.1–2.6) and ischaemic heart disease (SMR: 2.0; 95% CI: 1.8–2.1), were
doubled compared to the general population. Deaths from diseases of
the digestive system (SMR: 2.6; 95% CI: 2.2–2.9) and diabetes related
deaths (SMR: 2.2; 95% CI: 1.7–2.8)were elevated.We found little differ-
ence in mortality from cancers/neoplasms (SMR: 1.5; 95% CI: 1.4–1.6).
4. Discussion
We present what is to our knowledge the first study to assess mor-
tality in people with SMI drawn from both hospital inpatient and pri-
mary care records in a linked dataset. We have been able to identify
an ascertainment bias in previousmortality studieswhere patient inclu-
sion was based on hospitalisation alone (Hoang et al., 2011) or out-
patient and hospitalised secondary care cohorts (Jayatilleke et al.,
2017), or primary care records alone (Hayes et al., 2017; Osborn et al.,
2007). SMRs for people with SMI identified from hospital inpatient set-
tings weremore elevated than those identified in a primary care setting
or a combination of both. The higher SMRs observed from the secondary
care cohortmight be due to either shorter duration of follow-up periods
i.e., participants died sooner, or differences in disease severity between
the primary and secondary care cohorts. SMRs for participants in the
primary care cohort who were hospitalised were no different to those
not hospitalised (the latter includes those seen in out-patients). This
does not support the assumption of difference in disease severity be-
tween cohorts. It may reflect those within the secondary care cohort
who do not access primary care but are admitted through emergency
departments. It may also reflect differential ages between the cohorts
with older members of the hospitalised cohort more likely to have
late-onset psychotic disorders with potentially different aetiologies.
For all-cause mortality across data sources, our results were similar
to those reported in studies from secondary care settings. We found
people with SMI had a two to threefold higher death rate than the gen-
eral population. SMRs for individuals with schizophrenia related disor-
ders were higher than those with bipolar disorders. We also found the
mortality gap tended to decrease with age for all causes of death exam-
ined in the present study except for cerebrovascular disease andmental
behavioural disorders (dementia and substance misuse). This age-
dependent decrease in mortality has also been reported elsewhere
(Termorshuizen et al., 2013).
Using a similar categorisation strategy adopted in a previous study
(Termorshuizen et al., 2013), we computed SMRs associated with both
natural and unnatural causes of death. SMRs associated with unnatural
causes of death were found to be higher than those associatedwith nat-
ural ones and higher in males than in females. However, SMRs specifi-
cally associated with suicide, self-harm and undetermined intent were
higher in females.
In addition to all-cause mortality, we also report on a broad array of
underlying causes of death in those with SMI using a cohort sourced
from a combination of primary and secondary care settings. Some of
these causes are not commonly described elsewhere. In those with
SMI the highest SMRs were found from ill-defined and unknown causes
of death, suicide and substance abuse. Ill-defined and unknown causes
are often misclassifications of death from ischaemic heart disease and
Table 3
SMRs for cause-specific mortality in SMI stratified by gender and age.
SMR (95% CI)
Age (years)
No. of
deaths
Overall Male Female b45 45–64 65–84 ≥85
All causes 4709 2.6 (2.5–2.6) 3.0 (2.9–3.2) 2.3 (2.3–2.4) 5.8 (5.3–6.4) 3.3 (3.1–3.5) 2.4 (2.3–2.5) 2.0 (1.9–2.1)
Unnatural 441 6.9 (6.2–7.5) 7.3 (6.4–8.1) 5.9 (5.0–6.8) 10.0 (8.7–11.4) 9.9 (8.4–11.6) 3.5 (2.7–4.5) 2.3 (1.6–3.3)
Natural 4257 2.4 (2.3–2.5) 2.8 (2.7–2.9) 2.3 (2.2–2.3) 4.3 (3.7–4.8) 3.0 (2.8–3.2) 2.4 (2.3–2.5) 2.0 (1.8–2.1)
Circulatory diseases 1339 2.2 (2.0–2.3) 2.5 (2.3–2.8) 2.0 (1.9–2.1) 3.7 (2.8–4.9) 3.4 (3.0–3.8) 2.2 (2.0–2.3) 1.5 (1.4–1.7)
Ischaemic heart disease 585 2.0 (1.8–2.1) 2.5 (2.2–2.7) 1.7 (1.5–2.0) 3.7 (2.4–5.4) 2.9 (2.5–3.5) 2.0 (1.7–2.2) 1.4 (1.1–1.7)
Cerebrovascular disease 390 2.3 (2.1–2.6) 2.7 (2.3–3.2) 2.2 (1.9–2.5) 0.8 (0.1–2.6) 3.6 (2.7–4.7) 2.6 (2.2–2.9) 1.9 (1.6–2.3)
Other cerebrovascular 258 2.3 (2.0–2.6) 2.8 (2.3–3.4) 2.1 (1.8–2.4) 5.3 (3.2–8.3) 5.0 (3.8–6.4) 2.3 (1.9–2.7) 1.4 (1.1–1.8)
Other circulatory 106 2.3 (1.9–2.8) 2.1 (1.6–2.9) 2.3 (1.8–2.9) 6.0 (2.6–11.9) 3.6 (2.3–5.3) 2.1 (1.7–2.7) 1.1 (0.6–1.8)
Neoplasms 735 1.5 (1.4–1.6) 1.7 (1.5–1.8) 1.4 (1.3–1.6) 2.0 (1.5–2.7) 1.6 (1.4–1.9) 1.4 (1.3–1.5) 1.3 (1.1–1.6)
Gastrointestinal cancer 188 1.3 (1.2–1.5) 1.4 (1.1–1.7) 1.4 (1.1–1.7) 0.8 (0.2–2.2) 1.5 (1.1–1.9) 1.3 (1.1–1.6) 1.2 (0.8–1.8)
Lung cancer 176 1.7 (1.4–1.9) 1.9 (1.5–2.3) 1.6 (1.3–2.0) 4.7 (2.2–8.9) 1.7 (1.3–2.3) 1.5 (1.2–1.8) 2.0 (1.2–3.2)
Respiratory diseases 840 3.2 (3.0–3.4) 3.9 (3.5–4.4) 3.0 (2.7–3.3) 10.4 (7.2–14.6) 6.2 (5.3–7.2) 3.4 (3.1–3.7) 2.1 (1.8–2.4)
Pneumonia 418 3.8 (3.5–4.2) 5.2 (4.4–6.0) 3.3 (2.9–3.7) 10.7 (5.9–17.8) 9.1 (6.9–11.9) 5.1 (4.4–5.8) 2.2 (1.8–2.6)
COPD 233 2.5 (2.2–2.9) 3.1 (2.5–3.7) 2.3 (1.9–2.8) 15.9 (6.9–31.4) 5.7 (4.5–7.1) 2.2 (1.8–2.6) 1.2 (0.8–1.8)
Other respiratory diseases 28 1.8 (1.2–2.6) 1.7 (0.9–2.8) 2.3 (1.4–3.7) 15.6 (5.0–37.7) 2.5 (1.0–5.2) 1.6 (0.9–2.5) 0.9 (0.1–2.8)
Mental & behavioural disorders 489 5.7 (5.2–6.2) 7.6 (6.5–8.9) 4.9 (4.4–5.5) 9.5 (6.4–13.6) 11.2 (7.5–16.1) 6.3 (5.5–7.2) 4.7 (4.1–5.3)
Dementia 417 5.2 (4.7–5.7) 6.9 (5.7–8.2) 4.6 (4.1–5.1) 0.0 (0.0–0.0) 10.2 (5.2–18.3) 5.8 (5.0–6.6) 4.6 (4.0–5.2)
Substance abuse 35 8.2 (5.8–11.3) 8.3 (5.7–11.6) 5.4 (2.0–12.0) 9.3 (6.1–13.5) 5.5 (2.4–10.9) 10.6 (2.7–29.0) 0.0 (0.0–0.0)
Digestive system diseases 239 2.6 (2.2–2.9) 3.3 (2.8–3.9) 2.0 (1.6–2.4) 4.5 (3.3–6.1) 3.2 (2.6–4.0) 2.2 (1.8–2.7) 1.4 (1.0–2.1)
Other diseases of intestine & peritoneum 24 2.8 (1.8–4.1) 4.2 (2.1–7.4) 2.2 (1.2–3.6) 12.2 (2.0–40.2) 5.1 (2.1–10.7) 1.9 (1.0–3.4) 2.9 (1.2–6.1)
Peptic ulcer 21 2.4 (1.5–3.6) 2.3 (1.1–4.4) 2.5 (1.4–4.2) 3.8 (0.2–18.9) 1.9 (0.5–5.0) 2.8 (1.6–4.7) 1.5 (0.4–4.0)
Liver disease 78 2.5 (2.0–3.2) 3.0 (2.3–3.9) 1.9 (1.2–2.8) 3.9 (2.6–5.5) 2.4 (1.7–3.2) 1.6 (0.9–2.9) 2.1 (0.1–10.1)
Nervous system diseases 233 3.9 (3.5–4.5) 5.5 (4.5–6.5) 3.2 (2.6–3.8) 2.6 (1.2–5.0) 4.6 (3.4–6.3) 4.4 (3.7–5.2) 3.0 (2.3–4.0)
Parkinson's 77 5.4 (4.3–6.7) 8.3 (6.2–10.9) 3.9 (2.7–5.6) 126.6 (6.3–624.3) 15.3 (5.6–33.8) 5.7 (4.3–7.3) 3.6 (2.0–5.9)
Alzheimer's 85 3.8 (3.0–4.6) 6.0 (4.1–8.5) 3.0 (2.3–3.9) 0.0 (0.0–0.0) 1.5 (0.1–7.2) 4.8 (3.6–6.2) 2.8 (1.9–4.0)
Other diseases of the nervous system 39 2.8 (2.1–3.9) 3.6 (2.3–5.3) 2.3 (1.4–3.7) 4.0 (1.3–9.6) 4.1 (2.5–6.4) 2.2 (1.3–3.5) 1.8 (0.5–4.9)
Signs, symptoms & abnormal clinical findings 109 3.5 (2.9–4.3) 7.9 (5.8–10.4) 2.4 (1.9–3.1) 17.2 (11.8–24.3) 11.1 (7.0–16.9) 3.3 (1.8–5.5) 2.0 (1.5–2.6)
Ill-defined & unknown causes 55 13.3 (10.1–17.2) 14.0 (9.9–19.2) 11.8 (7.4–18.0) 17.7 (12.1–25.1) 12.2 (7.6–18.5) 7.1 (2.6–15.7) 6.6 (0.3–32.7)
Senility 53 2.1 (1.6–2.7) 3.3 (1.7–5.9) 1.8 (1.4–2.5) –a –a 2.8 (1.3–5.2) 2.0 (1.5–2.7)
Endocrine, nutritional & metabolic diseases 59 2.2 (1.7–2.8) 2.9 (1.9–4.1) 1.8 (1.3–2.6) 4.9 (2.3–9.3) 4.7 (2.9–7.2) 1.6 (1.1–2.4) 1.3 (0.6–2.3)
Diabetes 36 1.8 (1.3–2.4) 2.4 (1.5–3.7) 1.4 (0.9–2.2) 2.9 (0.5–9.7) 4.5 (2.4–7.7) 1.3 (0.7–2.1) 1.3 (0.6–2.5)
Infections & parasitic diseases 61 2.6 (2.0–3.4) 2.8 (1.8–4.3) 2.6 (1.9–3.5) 6.7 (2.5–15.0) 4.5 (2.5–7.5) 2.6 (1.8–3.7) 1.5 (0.8–2.6)
Septicaemia 31 3.0 (2.0–4.1) 3.3 (1.7–5.7) 2.8 (1.8–4.3) 9.8 (2.5–26.6) 3.3 (1.0–7.9) 3.2 (1.9–4.9) 1.8 (0.7–3.8)
Intestinal infections due to specified organisms 14 1.8 (1.0–3.0) 2.0 (0.6–4.8) 1.7 (0.9–3.1) 0.0 (0.0–0.0) 4.9 (0.8–16.2) 1.9 (0.9–3.7) 1.3 (0.4–3.1)
Genitourinary diseases 112 2.8 (2.3–3.4) 3.0 (2.1–4.1) 2.8 (2.2–3.5) 0.0 (0.0–0.0) 4.0 (2.0–7.1) 3.4 (2.6–4.3) 2.2 (1.6–3.0)
Glomerular & renal tubulo-interstitial diseases 19 4.9 (3.1–7.6) 8.7 (4.6–15.1) 3.2 (1.5–6.0) 0.0 (0.0–0.0) 4.7 (0.8–15.4) 5.5 (2.9–9.5) 4.8 (2.0–10.1)
Renal failure 20 1.6 (1.0–2.5) 1.4 (0.6–3.0) 1.8 (1.0–3.0) 0.0 (0.0–0.0) 3.7 (0.9–10.0) 1.2 (0.5–2.3) 1.9 (1.0–3.4)
Accidents (unintentional injuries) 219 4.8 (4.2–5.4) 6.1 (5.1–7.1) 3.3 (2.6–4.1) 8.1 (6.6–9.9) 8.2 (6.4–10.4) 2.4 (1.7–3.3) 2.2 (1.5–3.2)
Suicide, self-harm & undetermined intent 221 12.1 (10.6–13.8) 9.2 (7.7–10.8) 21.4 (17.1–26.4) 12.4 (10.3–14.7) 12.1 (9.6–15.1) 12.1 (7.9–17.9) 3.7 (0.2–18.5)
a SMR is not available for expected death equals to zero.
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160 A. John et al. / Schizophrenia Research 199 (2018) 154–162suicide (Lozano et al., 2001; Ohberg and Lonnqvist, 1998). Deaths from
cardiac arrhythmias are not detectable even at autopsy. Suicide may
also be misclassified due to the additional burden of proof i.e., beyond
reasonable doubt at the coroner's court. Previous studies have shown
that causes of death from ill-defined and unknown causes are more
common in marginal populations, specifically the homeless and the el-
derly living alone, but this is likely to also apply to those with SMI
(Andreev et al., 2008).
The lifetime risk of suicide for this population has been estimated to
be between 5%–13% (Hor and Taylor, 2010; Osborn et al., 2007; Pompili
et al., 2007). We found the suicide ratios for this population to be dis-
turbingly high, particularly for females. Death from suicide is three
times higher formales than females in the general population.However,
this disparity in rates does not follow for females with SMI. The psycho-
sismay diminish any inhibition to suicide that is present inwomen gen-
erally (Caldwell and Gottesman, 1990). We found that the SMR for
suicide was considerably higher in the cohort drawn from the hospital
inpatient setting than in the primary care sourced cohort. This is most
likely due to the difference in levels of severity between the cohorts.
This finding confirms previous studies in which suicide risk is highly as-
sociated with psychiatric hospitalisations. Approximately a third of the
suicides in people with schizophrenia occur during admission or the
first week after discharge (Nordentoft et al., 2013). SMRs due to psycho-
active substance abuse were unsurprisingly high in this population
when compared to the general population. In a UK study, 44% of com-
munitymental health patients had reported problem drug use or harm-
ful alcohol use in the previous year (Weaver et al., 2003).
SMRs associatedwith age-related cognitive decline diseases, such as
dementia and Alzheimer's were found to be particularly elevated. It is
possible that cognitive decline in schizophrenia may be misattributed
to dementia or it may be that those already in contact with psychiatric
services are more likely to be appropriately diagnosed than the general
population. Mortality ratios from pathogenic agents, includingmicroor-
ganisms leading to death from septicaemia and intestinal andperitoneal
infections and peptic ulcers were also very high. The elevated risk for
this population of developing peptic ulcers has been reported elsewhere
(Liao et al., 2014). It may be that symptoms are under-reported or
under- diagnosed by those with SMI so they present late to services.
However, immune system dysfunction and the involvement of infec-
tious agents in the pathophysiology of these psychiatric diseases, in-
cluding antimicrobial defence, are being reported (Yolken et al., 2016).
SMRs for respiratory diseases were also very high in comparison to
the general population, particularly pneumonia. This can be perhaps ex-
plained by higher rates of smoking in this population (Olfson et al.,
2015). We found a two and a half fold increased risk of death from car-
diovascular disease in peoplewith SMI, but this was lower than SMRs in
neurological disorders, cognitive decline, infections and respiratory dis-
eases. Despite this, given that cardiovascular disease is the most com-
mon cause of death in both general and the SMI populations in
Western countries, much of the excess mortality in people with SMI
will be attributable to this disease group (Osborn et al., 2007; Osborn
et al., 2006). Similarly, we found death rates from cancers, which al-
though slightly elevated, did not result in the highest disparities com-
pared to the general population, which is in keeping with findings
from many other studies (Kisely et al., 2013; Osborn et al., 2007).
4.1. Strengths and limitations
We believe this is the first study to evaluate mortality for people
with SMI drawn from both primary care and secondary inpatient care
settings in linked data. This population-wide observational study thus
encompasses the spectrum of severity of SMI of those engagedwith ser-
vices. However, some vulnerable groups, e.g., the homeless, may not be
registered with a GP and would not be included. The combination of
both settings balances some of the weaknesses of each alone. However,
potential confounders may be that if an individual has a physicaldisorder and visits a GP theymay be more likely to receive an SMI diag-
nosis. Two previous studies have made direct comparisons of mortality
risks between inpatient and outpatients for this population to establish
the over-estimation (Amaddeo et al., 1995; Crump et al., 2013) when
compared to studies based solely on in-patients (Hoang et al., 2011).
Ideally, we would have included those with SMI seen in out-patients.
However in the United Kingdom, diagnostic coding (rather than spe-
cialty coding) in the out-patient dataset is too poor to utilise in studies
of this type. Letters received from out-patients are Read coded in the
primary care dataset. The diagnostic codes to create our cohorts have
been previously validated (Economou et al., 2012; Lloyd et al., 2015).
A further strength is that we have coverage of deaths for the whole
general population. It is unclear, but likely, in other similar studies con-
ducted in theUK that the linkage of themortality dataset is to a subset of
the population. If our study had been restricted to those present in the
hospital episode statistics/admissions dataset with or without SMI,
only 54.9% of those with an SMI diagnosis in the combined cohort
would have been linked to the mortality dataset (16,371/29,797). Sim-
ilarly most primary care databases are sampled i.e., studies based in The
Health Improvement Network (Hayes et al., 2017), cover a sampled
population of 6% of the United Kingdom population, whereas SAIL pro-
vides population level data of 74% of the Wales population allowing
whole general population linkage of mortality. Also by calculating
SMRs for underlying cause of death using the expected rates from the
specific corresponding causes in the general population of Wales, we
believe that the relative excess can be accurately determined.
A further advantage is that we have included some underlying
causes of death rarely reported elsewhere, for example, Hayes et al.
(2017) report mortality from all causes, cardiovascular disorders and
suicide only. Similarly in a study based in a large secondary care data-
base in London, reduced life expectancy in those with SMI was
accounted for by a wide range of major grouped causes of death but
these were limited to circulatory, cancer, respiratory, digestive, suicide,
other external and all other causes (Jayatilleke et al., 2017). Larger co-
horts may identify further causes yielding even higher rates,
e.g., epilepsy. We were restricted by the size of the cohort as to how
many specific causes we could reasonably include. Other limitations in-
clude the usual caveats of the use of routine data (not collected primar-
ily for research purposes, quality and completeness issues) and accuracy
of death certification, particularly for suicide (Gunnell et al., 2011).
Indirect standardisation was used for the calculation of SMRs, which
means we cannot quantify the differences in premature mortality be-
tween our specified cohorts; only in relation to the general population
since population structures within each cohort may vary.
Some authors argue that life expectancy is a preferable measure of
mortality to the SMR (Jayatilleke et al., 2017), primarily since it is easier
to interpret and communicate, particularly for laypeople and clinicians
working outside of academia. However, computation of this statistic
has a number of difficulties. For example, its reliance on the construc-
tion of current life-tables makes it impractical for routine use, while
for small populations computation of life expectancy may not be possi-
ble at all (Silcocks et al., 2001; Tsai et al., 1992).
4.2. Implications for policy, practice and future research
Methodological considerations and comprehensive
characterisations of mortality in this patient population are important
when informing policy initiatives that improve services and target in-
terventions. By including people from both primary and secondary
care in this study we highlight the need for better integration not only
between specialty teams within hospitals, but also between primary
and secondary care, particularly since secondary caremental health ser-
vices are under increasing pressure to discharge people back to primary
care earlier (Rethink Mental Illness, 2012). Therefore, the development
of policies to: expand the remit of liaison psychiatry services fromexclu-
sively hospital based into community settings (Department of Health,
161A. John et al. / Schizophrenia Research 199 (2018) 154–1622014); further develop health promotion interventions for unhealthy
lifestyle behaviours; and improve screening opportunities for early de-
tection and intervention is welcomed. It may be worth reflecting on
investing, targeting and delivering lifestyle interventions to improve
physical health care for people with SMI in secondary care settings,
which is currently poor (Bailey et al., 2012; Crawford et al., 2014;
Royal College of Psychiatrists, 2015).
Previous studies may have over- or under-estimated premature
mortality in people with SMI to some extent but, as we have demon-
strated, SMRs are raised in all settings by an unacceptable ratio. There-
fore previous literature has had appropriate major policy implications
for improving the physical health of people with SMI. The significant
emphasis on improving physical health care for people with SMI
through screening for cardiovascular and metabolic disorders is impor-
tant to address this health injustice, but our study suggests this could be
broadened to, for example, peptic ulcers and early recognition and
treatment of infection.
Our results demonstrate that suicide prevention in this population is
an important and appropriate focus of national policy. However, a
greater emphasis on suicide prevention in community settings in this
group should be considered. Suicide rates under crisis resolution and
home treatment teams were found to be higher (14.6 per 10,000 epi-
sodes) than that under psychiatric hospital admission (8.8 per 10,000
admission) in a recent report (Hunt et al., 2014).
Future studies should explore prematuremortality in thosewith SMI
using both primary and secondary care sources of cases. This includes
whether the all-cause mortality gap has increased differentially over
the last decade in those with hospital admissions compared to that
demonstrated in primary care data (Hayes et al., 2017). Studies from
secondary care demonstrate the excess mortality persists, but more re-
cent comprehensive studies are essential (Chang et al., 2011). Long term
studies are also needed to determine the extent and interaction be-
tween antipsychotic treatment, metabolic indicators, lifestyle choices,
social deprivation, age and genetics that lead to premature mortality,
particularly from certain diseases. In our whole population-based
study we found some of the highest mortality ratios in causes not
often commonly described elsewhere, such as deaths from unexplained
causes, neurological disorders, cognitive decline, infections and respira-
tory diseases.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
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